The AMAGE guidelines: Metabolic dysfunction-associated fatty liver disease through a regional lens [0.03%]
Said A Al-Busafi,Mohammed Eslam
Said A Al-Busafi
Association of nonselective β blockers with the development of hepatocellular carcinoma in liver cirrhosis: a meta-analysis [0.03%]
Yan Xu,Xiaohe Wang,Xiangdong Li et al.
Yan Xu et al.
Introduction and objectives: Nonselective β blockers (NSBBs) may be involved in reducing gut-derived inflammation and intrahepatic inflammation to prevent hepatocellular carcinoma (HCC). This study aimed to systematicall...
Comment on "A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma" [0.03%]
关于“三种基因耐药谱作为肝细胞癌预后工具”的评论
Xiaoqi Sun,Yongming Zhou,Hailin Chen
Xiaoqi Sun
Learning is not enough: enhancing the reach and rigor of hepatitis eLearning [0.03%]
学习还不够：提高戊肝在线教育的影响力和严谨性
Gizem Zorlu Gorgulugil,Yasin Sahinturk,Gokhan Koker
Gizem Zorlu Gorgulugil
Liver transplant outcomes in primary biliary cholangitis and metabolic dysfunction-associated steatotic liver disease overlap [0.03%]
原发性胆汁性胆管炎和代谢功能障碍相关脂肪肝重叠患者的肝脏移植结局
Leandro Sierra,Shahana Prakash,Jamak Modaresi Esfeh et al.
Leandro Sierra et al.
Introduction and objectives: Primary biliary cholangitis (PBC) frequently overlaps with metabolic dysfunction-associated steatotic liver disease (MASLD). The impact of concurrent MASLD on liver transplant (LT) in PBC rema...
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities [0.03%]
美国四大城市初级保健提供者对代谢功能异常相关性脂肪肝疾病(MASLD)的认识
Jeffrey V Lazarus,Trenton M White,Melina Manolas et al.
Jeffrey V Lazarus et al.
Introduction and objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease but remains widely under-recognized in primary care. The 2023 shift from "nonalcoholic...
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis [0.03%]
代谢功能紊乱相关脂肪肝病合并纤维化的理想筛查标准
Byeong Geun Song,Myung Ji Goh,Wonseok Kang et al.
Byeong Geun Song et al.
Introduction and objectives: Early detection of metabolic dysfunction-associated steatotic liver disease (MASLD) with fibrosis may facilitate interventions that can prevent disease progression and may justify screening. H...
Can liver biopsy be spared for the diagnosis of autoimmune hepatitis in selected children? A multicenter retrospective study [0.03%]
选择性儿童能否免于活检以诊断自身免疫性肝炎？多中心回顾性研究
Valeria Delle Cave,Fabiola Di Dato,Pier Luigi Calvo et al.
Valeria Delle Cave et al.
Introduction and objectives: Autoimmune hepatitis (AIH) is diagnosed based on clinical, biochemical, immunological, and histological parameters, and on the exclusion of other liver diseases. Multiple scoring systems are a...
Long-term systemic effects of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/MAFLD) in children: a systematic review of persistence and progression into adulthood [0.03%]
儿童代谢紊乱相关脂肪肝病（MASLD，之前称为NAFLD/MAFLD）的长期全身影响：对持续性和向成人期进展的系统评价
Beatriz Rey-Garcia,Maria Teresa Reyes-Chacon,Eduardo Rosas-Blum et al.
Beatriz Rey-Garcia et al.
Metabolic dysfunction associated steatotic liver disease (MASLD), previously referred to as nonalcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD), is increasingly prevalent among obese children and ad...
Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology [0.03%]
重新评估sIL-6在阿特珠单抗联合贝伐珠单抗治疗肝癌免疫治疗中的预后价值：基线肝脏功能和病因学的关键作用
Min Zou,Shiye Yang,Jinkai Feng et al.
Min Zou et al.